More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

BioArctic AB’s partner Eisai presented real-world Lecanemab results from the LEADER Study in early Alzheimer’s, noting that nearly 83% of enrolled early AD patients met the study’s enrollment outcomes/criteria. The update is supportive of the program’s real-world profile, but details on clinical endpoints and durability are not provided in the excerpt.

Analysis

BioArctic AB’s partner Eisai presented real-world Lecanemab results from the LEADER Study in early Alzheimer’s, noting that nearly 83% of enrolled early AD patients met the study’s enrollment outcomes/criteria. The update is supportive of the program’s real-world profile, but details on clinical endpoints and durability are not provided in the excerpt.